The interleukin-1 (IL-1) receptor antagonist (IL-1ra) is an endogenous antagonist that blocks the effects of the proinflammatory cytokines IL-1 and IL-1 by occupying the type I IL-1 receptor. Here we describe transgenic mice with astrocyte-directed overexpression of the human secreted IL-1ra (hsIL-1ra) under the control of the murine glial fibrillary acidic protein (GFAP) promoter. Two GFAP-hsIL-1ra strains have been generated and characterized further: GILRA2 and GILRA4. These strains show a brain-specific expression of the hsIL-1ra at the mRNA and protein levels. The hsIL-1ra protein was approximated to ~50 ng/brain in cytosolic fractions of whole brain homogenates, with no differences between male and female mice or between the two strains. Furthermore, the protein is secreted, inasmuch as the concentration of hsIL-1ra in the cerebrospinal fluid was 13 (GILRA2) to 28 (GILRA4) times higher in the transgenic mice than in the control animals. To characterize the transgenic phenotype, GILRA mice and nontransgenic controls were injected with recombinant human IL-1 (central injection) or lipopolysaccharide (LPS, peripheral injection). The febrile response elicited by IL-1 (50 ng/mouse icv) was abolished in hsIL-1ra-overexpressing animals, suggesting that the central IL-1 receptors were occupied by antagonist. The peripheral LPS injection (25 µg/kg ip) triggered a fever in overexpressing and control animals. Moreover, no differences were found in LPS-induced (100 and 1,000 µg/kg ip; 1 and 6 h after injection) IL-1 and IL-6 serum levels between GILRA and wild-type mice. On the basis of these results, we suggest that binding of central IL-1 to central IL-1 receptors is not important in LPS-induced fever or LPS-induced IL-1 and IL-6 plasma levels.

glial fibrillary acidic protein promoter; lipopolysaccharide; interleukin-1; cytokine

This article has been cited by other articles:

				M. D. Josephs, C. C. Solorzano, M. Taylor, J. J. Rosenberg, D. Topping, A. Abouhamze, S. L. D. Mackay, E. Hirsch, D. Hirsh, M. Labow, et al. Modulation of the acute phase response by altered expression of the IL-1 type 1 receptor or IL-1ra Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2000; 278(4): R824 - R830. [Abstract] [Full Text] [PDF]

				A. Inui Transgenic Approach to the Study of Body Weight Regulation Pharmacol. Rev., March 1, 2000; 52(1): 35 - 62. [Abstract] [Full Text] [PDF]

				A. Vezzani, D. Moneta, M. Conti, C. Richichi, T. Ravizza, A. De Luigi, M. G. De Simoni, G. Sperk, S. Andell-Jonsson, J. Lundkvist, et al. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice PNAS, October 10, 2000; 97(21): 11534 - 11539. [Abstract] [Full Text] [PDF]